Presentation (CTI)

OBJECTIVES: The objective of this review is to evaluate the potential financial and policy impact of the Centers for Medicare & Medicaid Services’ (CMS) GENEROUS model, an initiative designed to reduce Medicaid drug spending by delinking manufacturer reimbursement from utilization, instead anchoring payment to international reference pricing. The analysis aimed to determine whether the model is likely to generate cost savings for state and federal Medicaid programmes while maintaining access to clinically valuable therapies.
METHODS: A targeted review was conducted using publicly available CMS documentation, model descriptions, policy briefs, and analogous payment models. Particular attention was given to models’ pricing mechanics, including the calculation of the Guaranteed Net Unit Price using the most-favored nation benchmark, and their integration with existing rebate structures. Comparative assessment drew on evidence from global budget models and previous CMS episode‑based payment initiatives, focusing on financial outcomes and design features associated with cost savings.
RESULTS: The GENEROUS model establishes a delinked, value‑based payment structure in which Medicaid pays manufacturers a price aligned with the second‑lowest net price from a basket of countries, adjusted using purchasing‑power parity. This framework provides predictable revenue for manufacturers while preventing incentives for over‑prescribing. Evidence from comparable reforms demonstrates that tightly engineered price‑based models can yield substantial payer savings. For example, global hospital budgets have produced meaningful expenditure reductions, and refinements to CMS’s episode‑based models have generated savings when pricing and discount parameters are rigorously defined.
CONCLUSIONS: Current evidence indicates that the GENEROUS model has a credible theoretical pathway to delivering sustained cost savings. Its success in the real world will depend on broad state participation, manufacturer engagement with delinked pricing, robust price‑validation mechanisms, and alignment with existing rebate frameworks. If effectively executed, the model offers a scalable and sustainable approach to improving access to high‑value therapies while reducing Medicaid expenditures.